AllianceBernstein’s Editas Medicine EDIT Stock Holding History

AllianceBernstein’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$464K	Buy	187,930 +20,400	+12%	+$59.6K	﹤0.01%	2764
2026 Q1	$343K	Hold	167,530	–	–	﹤0.01%	2822
2025 Q4	$343K	Hold	167,530	–	–	﹤0.01%	2844
2025 Q3	$581K	Sell	167,530 -16,160	-9%	-$45.1K	﹤0.01%	2601
2025 Q2	$404K	Buy	183,690 +50,060	+37%	+$81.9K	﹤0.01%	2771
2025 Q1	$155K	Hold	133,630	–	–	﹤0.01%	2985
2024 Q4	$170K	Sell	133,630 -1,200	-0.9%	-$3.06K	﹤0.01%	3055
2024 Q3	$460K	Hold	134,830	–	–	﹤0.01%	2696
2024 Q2	$630K	Buy	134,830 +52,330	+63%	+$295K	﹤0.01%	2533
2024 Q1	$612K	Hold	82,500	–	–	﹤0.01%	2496
2023 Q4	$836K	Hold	82,500	–	–	﹤0.01%	2362
2023 Q3	$644K	Sell	82,500 -4,100	-5%	-$35.2K	﹤0.01%	2447
2023 Q2	$713K	Buy	86,600 +4,100	+5%	+$35.7K	﹤0.01%	2466
2023 Q1	$598K	Hold	82,500	–	–	﹤0.01%	2474
2022 Q4	$732K	Hold	82,500	–	–	﹤0.01%	2433
2022 Q3	$1.01M	Hold	82,500	–	–	﹤0.01%	2283
2022 Q2	$976K	Sell	82,500 -4	-0%	-$54	﹤0.01%	2358
2022 Q1	$1.57M	Buy	82,504 +200	+0.2%	+$3.72K	﹤0.01%	2227
2021 Q4	$2.19M	Hold	82,304	–	–	﹤0.01%	2087
2021 Q3	$3.38M	Hold	82,304	–	–	﹤0.01%	1832
2021 Q2	$4.66M	Hold	82,304	–	–	﹤0.01%	1665
2021 Q1	$3.46M	Buy	82,304 +504	+0.6%	+$28.7K	﹤0.01%	1778
2020 Q4	$5.74M	Hold	81,800	–	–	﹤0.01%	1411
2020 Q3	$2.29M	Buy	81,800 +400	+0.5%	+$13K	﹤0.01%	1776
2020 Q2	$2.41M	Buy	81,400 +13,300	+20%	+$348K	﹤0.01%	1748
2020 Q1	$1.35M	Buy	68,100 +700	+1%	+$17.7K	﹤0.01%	1888
2019 Q4	$2M	Buy	67,400 +1,200	+2%	+$30K	﹤0.01%	1969
2019 Q3	$1.5M	Hold	66,200	–	–	﹤0.01%	2079
2019 Q2	$1.64M	Hold	66,200	–	–	﹤0.01%	2085
2019 Q1	$1.62M	Sell	66,200 -58,400	-47%	-$1.32M	﹤0.01%	2017
2018 Q4	$2.83M	Buy	124,600 +59,100	+90%	+$1.61M	﹤0.01%	1634
2018 Q3	$2.08M	Buy	65,500 +900	+1%	+$29.1K	﹤0.01%	1908
2018 Q2	$2.31M	Sell	64,600 -20,070	-24%	-$711K	﹤0.01%	1813
2018 Q1	$2.81M	Buy	84,670 +42,070	+99%	+$1.5M	﹤0.01%	1592
2017 Q4	$1.31M	Buy	42,600 +900	+2%	+$22.7K	﹤0.01%	2122
2017 Q3	$1M	Hold	41,700	–	–	﹤0.01%	2282
2017 Q2	$700K	Buy	41,700 +17,500	+72%	+$315K	﹤0.01%	2475
2017 Q1	$540K	Hold	24,200	–	–	﹤0.01%	2511
2016 Q4	$393K	Hold	24,200	–	–	﹤0.01%	2641
2016 Q3	$326K	Buy	24,200 +7,600	+46%	+$156K	﹤0.01%	2673
2016 Q2	$405K	Buy	+16,600	New	+$560K	﹤0.01%	2586

Other funds holding EDIT

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

AllianceBernstein's EDIT Position: Q2 2026 in Review

AllianceBernstein increased its Editas Medicine (EDIT) stake by 12% in Q2 2026, buying an estimated $59.6K and bringing the position to 187,930 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

AllianceBernstein first reported a position in EDIT in Q2 2016 and has held it in 41 quarters since. The position peaked at $5.74M in Q4 2020. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

AllianceBernstein held 187,930 shares of Editas Medicine worth $464K as of Q2 2026.
AllianceBernstein bought 20,400 Editas Medicine shares in Q2 2026, an estimated $59.6K.
Editas Medicine made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2764 holding.
AllianceBernstein first reported a position in Editas Medicine in Q2 2016 and has held it in 41 quarters since.
AllianceBernstein's Editas Medicine position peaked at $5.74M in Q4 2020.
214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.